PE20081556A1 - Formas cristalinas de glyt1 - Google Patents

Formas cristalinas de glyt1

Info

Publication number
PE20081556A1
PE20081556A1 PE2008000055A PE2008000055A PE20081556A1 PE 20081556 A1 PE20081556 A1 PE 20081556A1 PE 2008000055 A PE2008000055 A PE 2008000055A PE 2008000055 A PE2008000055 A PE 2008000055A PE 20081556 A1 PE20081556 A1 PE 20081556A1
Authority
PE
Peru
Prior art keywords
glyt1
pain
referred
crystal shapes
peaks
Prior art date
Application number
PE2008000055A
Other languages
English (en)
Inventor
Andre Budendorf
Annette Deynet-Vucenovic
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E Rohrer
Urs Schwitter
Ralph Diodone
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081556A1 publication Critical patent/PE20081556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRSITALINA A DE LA [4-(3-FLUOR-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANOSULFONIL-2-((S)-2,2,2-TRIFLUOR-1-METIL-ETOXI)-FENIL]-METANONA, CARACTERIZADA POR LO MENOS DE 3 PICOS ELEGIDOS ENTRE LOS PICOS DE DIFRACCION DE RAYOS X OBTENIDOS CON REDIACION CuKALFA, EXPRESADOS EN 2-THETA=13,1; 14,3; 15,4; 16,2; 17,1; 17,2; 17,6; 18,0; 19,8; 20,1; 20,4; 21,0; 22,6 Y 24,3. REFERIDA TAMBIEN A LAS FORMAS CRISTALINAS B, C Y UNA FORMA AMORFA. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS CRISTALES SON UTILES EN EL TRATAMIENTO DE DOLOR, PSICOSIS, DOLOR, ESQUIZOFRENIA, DEMENCIA, ENTRE OTROS
PE2008000055A 2006-12-28 2008-01-02 Formas cristalinas de glyt1 PE20081556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28

Publications (1)

Publication Number Publication Date
PE20081556A1 true PE20081556A1 (es) 2008-11-28

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000055A PE20081556A1 (es) 2006-12-28 2008-01-02 Formas cristalinas de glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (es)
EP (1) EP2114405B1 (es)
JP (1) JP4799666B2 (es)
KR (1) KR101130146B1 (es)
CN (1) CN101573114A (es)
AR (1) AR064545A1 (es)
AU (1) AU2007341356B2 (es)
BR (1) BRPI0720829B8 (es)
CA (1) CA2673667A1 (es)
CL (1) CL2007003830A1 (es)
CO (1) CO6190613A2 (es)
CR (1) CR10846A (es)
CY (1) CY1116350T1 (es)
DK (1) DK2114405T3 (es)
EC (1) ECSP099471A (es)
ES (1) ES2535040T3 (es)
HR (1) HRP20150573T1 (es)
HU (1) HUE025032T2 (es)
MA (1) MA31029B1 (es)
MX (1) MX2009006859A (es)
MY (1) MY188367A (es)
NO (1) NO342150B1 (es)
NZ (1) NZ577502A (es)
PE (1) PE20081556A1 (es)
PL (1) PL2114405T3 (es)
PT (1) PT2114405E (es)
RS (1) RS53910B1 (es)
RU (1) RU2463295C2 (es)
SI (1) SI2114405T1 (es)
TW (1) TWI388552B (es)
UA (1) UA100232C2 (es)
WO (1) WO2008080821A1 (es)
ZA (1) ZA200904423B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080821A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
WO2013174694A1 (en) * 2012-05-25 2013-11-28 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
WO2022241274A1 (en) * 2021-05-14 2022-11-17 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
MXPA06001665A (es) * 2003-08-11 2006-04-28 Hoffmann La Roche Piperazina con grupo fenilo sustituido -or y su uso como inhibidores del transportador de glicina 1 (glyt-1).
WO2008080821A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1

Also Published As

Publication number Publication date
JP2010514725A (ja) 2010-05-06
US20100311971A1 (en) 2010-12-09
US20110295007A1 (en) 2011-12-01
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
TWI388552B (zh) 2013-03-11
CY1116350T1 (el) 2017-03-15
HUE025032T2 (en) 2016-02-29
ECSP099471A (es) 2009-07-31
KR20090094166A (ko) 2009-09-03
TW200833677A (en) 2008-08-16
BRPI0720829B1 (pt) 2020-04-07
BRPI0720829A2 (pt) 2014-02-25
ES2535040T3 (es) 2015-05-04
HRP20150573T1 (en) 2015-07-03
KR101130146B1 (ko) 2012-03-28
MY188367A (en) 2021-12-06
SI2114405T1 (sl) 2015-06-30
CR10846A (es) 2009-08-12
CN101573114A (zh) 2009-11-04
ZA200904423B (en) 2010-05-26
NO20092358L (no) 2009-06-22
PT2114405E (pt) 2015-06-02
MA31029B1 (fr) 2009-12-01
CA2673667A1 (en) 2008-07-10
CL2007003830A1 (es) 2008-07-11
BRPI0720829B8 (pt) 2021-05-25
US20120309969A1 (en) 2012-12-06
WO2008080821A1 (en) 2008-07-10
US20080214561A1 (en) 2008-09-04
RU2009124113A (ru) 2011-02-10
AU2007341356A1 (en) 2008-07-10
RS53910B1 (en) 2015-08-31
CO6190613A2 (es) 2010-08-19
US8039473B2 (en) 2011-10-18
NO342150B1 (no) 2018-04-03
DK2114405T3 (en) 2015-04-07
MX2009006859A (es) 2009-07-03
AR064545A1 (es) 2009-04-08
NZ577502A (en) 2012-02-24
EP2114405B1 (en) 2015-03-11
PL2114405T3 (pl) 2015-08-31
UA100232C2 (uk) 2012-12-10
RU2463295C2 (ru) 2012-10-10
US20130197225A1 (en) 2013-08-01
JP4799666B2 (ja) 2011-10-26

Similar Documents

Publication Publication Date Title
PE20081556A1 (es) Formas cristalinas de glyt1
CY1121583T1 (el) Πολυμορφικες και ψευδοπολυμορφικες μορφες της φαρμακευτικης ενωσης nxl104
PE20060372A1 (es) Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
ECSP11011309A (es) Nueva forma cristalina vi de la agomelatina, preparación y uso de la misma
PE20071016A1 (es) Formas cristalinas de n-(benzo[b]tien-3-ilmetil)-sulfamida
AR054777A1 (es) Modificaciones cristalinas de piraclostrobina
CR8249A (es) Forma cristalina gamma del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que lo contienen
PE20081251A1 (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
CR8529A (es) Nueva forma cristalina v de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contiene
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
PE20061009A1 (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparacion, y composiciones farmaceuticas que la contienen
AR034259A1 (es) Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
NO20045037L (no) Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form
AR051043A1 (es) Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
CR20170556A (es) UNA FORMA CRISTALINA DE CLORHIDRATO DE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL) BENZO[B] TIOFENO-2-CARBOXAMIDA MONOHIDRATO (Divisional 2012-0585)
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
RS54361B1 (en) CORTEXOLONE-17ALFA-PROPIONATE IN CRYSTAL HYDRATE FORM IV
AR084832A1 (es) Derivado cristalino de oxazina
AR078627A1 (es) N-((1r,2s,5r)-5-terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, forma cristalina, procedimiento de preparacion, composiciones farmaceuticas que los comprenden y uso del mismo para tratar diabetes, obesidad, enfermedades alerg
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
ECSP088153A (es) Nuevos derivados de piperidina
AR062204A1 (es) Formas solidas de (3'-clorobifeni-4-il)(1-pirimidin-2-il)piperidin-4-il)metanona, un metodo de preparacion, una dosificacion farmaceutica que la comprende y su uso en eltratamiento de trastornos cognitivos y de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FC Refusal